Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 24.46
-1.77 %
$ 991 M
Market Cap
56.88
P/E
INCOME STATEMENT
1.02 B
REVENUE
53.3 M
OPERATING INCOME
2.42 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Phibro Animal Health Corporation
| Revenue | 1.02 B |
| Cost Of Revenue | 705 M |
| Gross Profit | 312 M |
| Operating Expenses | 260 M |
| Operating Income | 53.3 M |
| Other Expenses | 50.9 M |
| Net Income | 2.42 M |
Income Statement
Millions
| Jun-2024 | Jun-2023 | Jun-2022 | Jun-2021 | Jun-2020 | Jun-2019 | Jun-2018 | Jun-2017 | Jun-2016 | Jun-2015 | Jun-2014 | Jun-2013 | Jun-2012 | Jun-2011 | Jun-2010 | Jun-2009 | Jun-2008 | Jun-2007 | Jun-2006 | Jun-2005 | Jun-2004 | Jun-2003 | Jun-2002 | Jun-2001 | Jun-2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||||||||||||||||
| Revenue | 1 017.7 | 977.9 | 942.3 | 833.4 | 800.4 | 828.0 | 820.0 | 764.3 | 751.5 | 748.6 | 691.9 | 653.2 | 654.1 | 618.3 | 594.2 | 537.1 | 511.4 | 453.0 | 398.4 | 364.4 | 354.4 | 337.8 | 328.7 | 319.7 | 323.0 |
| GROSS PROFIT | |||||||||||||||||||||||||
| Cost Of Revenue | 705.2 | 679.7 | 656.9 | 562.0 | 543.5 | 563.4 | 553.1 | 516.0 | 512.5 | 512.2 | 484.1 | 474.2 | 490.0 | 471.7 | 439.5 | 407.5 | 389.7 | 341.8 | 307.3 | 293.1 | 265.2 | 248.6 | 247.4 | 250.3 | 249.6 |
| Gross Profit | 312.5 | 298.2 | 285.4 | 271.4 | 256.9 | 264.6 | 266.9 | 248.3 | 239.0 | 236.4 | 207.8 | 179.0 | 164.1 | 146.7 | 154.7 | 129.6 | 121.7 | 111.2 | 91.1 | 71.3 | 89.2 | 89.2 | 81.3 | 69.4 | 73.4 |
| OPERATING INCOME | |||||||||||||||||||||||||
| Operating Expenses | 260.3 | 226.4 | 206.4 | 196.5 | 187.7 | 181.4 | 168.0 | 150.3 | 153.3 | 148.7 | 144.0 | 122.2 | 114.8 | 105.4 | 101.9 | 88.2 | 92.4 | 90.2 | 68.1 | 66.9 | 45.5 | 63.3 | 70.6 | 63.9 | 57.8 |
| Selling, General and Administrative Expenses | 220.9 | 226.4 | 206.4 | 196.5 | 187.7 | 181.4 | 168.0 | 150.3 | 153.3 | 148.7 | 144.0 | 122.2 | 114.8 | 105.4 | 101.9 | 84.6 | 81.3 | 76.2 | 68.1 | 66.9 | 63.4 | 63.3 | 70.6 | 63.9 | 59.3 |
| Research and Development Expenses | 29.2 | 24.4 | 20.8 | 17.8 | 13.7 | 12.1 | 10.0 | 9.4 | 11.0 | 9.5 | 8.2 | 6.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 53.3 | 71.8 | 46.3 | 43.0 | 36.9 | 73.3 | 98.9 | 97.9 | 85.7 | 87.7 | 63.8 | 56.7 | 49.3 | 41.2 | 52.8 | 41.4 | 29.3 | 21.1 | 23.0 | 4.4 | 43.7 | 25.9 | 10.6 | 5.4 | 15.7 |
| PRE-TAX INCOME | |||||||||||||||||||||||||
| Interest Income Expense | 22.0 | 17.9 | 11.9 | 12.9 | 12.9 | 11.8 | 11.9 | 14.9 | 16.6 | 14.6 | 33.0 | 35.8 | 35.7 | 34.6 | (33.1) | (43.4) | (26.9) | (27.3) | (32.6) | (26.9) | (20.6) | (17.4) | (17.7) | (17.7) | (14.2) |
| Total Other Income | (42.4) | (17.8) | (6.7) | (8.4) | (13.7) | (11.7) | (10.9) | (17.4) | (19.4) | (8.9) | (57.5) | (38.9) | (36.2) | (49.1) | (33.2) | (43.5) | (27.4) | (27.4) | (30.9) | (25.8) | (19.8) | (18.9) | (21.0) | (17.1) | (1.7) |
| Pre-Tax Income | 10.9 | 54.1 | 72.3 | 66.5 | 55.5 | 71.5 | 88.1 | 80.5 | 76.8 | 78.8 | 6.3 | 17.8 | 13.1 | (7.9) | 19.6 | (2.1) | 1.9 | (6.3) | (7.9) | (21.4) | 23.9 | 7.0 | (10.4) | (11.7) | 14.0 |
| NET INCOME | |||||||||||||||||||||||||
| Tax Provision | 8.5 | 21.5 | 23.2 | 12.1 | 22.0 | 16.8 | 23.2 | 15.9 | (6.0) | 18.5 | 9.4 | (7.0) | 6.1 | 5.0 | 3.8 | 3.4 | 2.6 | 0.4 | 5.2 | 2.1 | 7.8 | 9.8 | 14.8 | (0.4) | 3.9 |
| Net Income | 2.4 | 32.6 | 49.2 | 54.4 | 33.6 | 54.7 | 64.9 | 64.6 | 82.7 | 60.3 | (3.1) | 24.9 | 7.0 | (12.9) | 42.1 | (8.3) | 2.2 | (6.7) | (13.1) | (22.1) | 12.9 | (17.6) | (51.8) | (14.9) | 10.1 |
| EPS | 0.0596 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | 1.63 | 2.11 | 1.55 | 0.0991 | 0.82 | 0.23 | 0.42 | 1.09 | 0.21 | 0.0567 | 0.17 | 0.22 | 0.37 | 0.22 | 0.29 | 0.86 | 0.25 | 0.17 |